Polecompetitivite

DGCIS_CMJN_bleu

Ubifrance-logo
France-logo

Request Meetings with US Companies in San Francisco

Profiles of attending companies are listed below. PLEASE CHECK THIS WEBSITE REGULARLY FOR AN UPDATED LIST.

The DEADLINE to submit your meeting requests is OCTOBER, 5th.

THE PROCESS:

  1. You will receive a confirmation email for each request made
  2. UBIFRANCE will begin processing all meeting requests from October, 5th, 2012, and will confirm mutual interest from the other party
  3. A provisional schedule will be sent to you a few days before the event and a finalized schedule on the day of the event

If you have any questions about this process, please CONTACT US.

In order to improve your chances of meeting with the companies of your choice, make your meeting requests as specific, simple and direct as possible. Include information about what your company can offer and what your company is looking for.




Default_logo

Acumen Pharmaceuticals, Inc.

visit website request a meeting with this company
Acumen Pharmaceuticals Inc. is engaged in the discovery and development of therapeutics and diagnostics related to soluble amyloid-beta (Abeta) oligomers in Alzheimer’s disease.
More ?
COMPANY :
Acumen Pharmaceuticals Inc. is engaged in the discovery and development of therapeutics and diagnostics related to soluble amyloid-beta (Abeta) oligomers in Alzheimer’s disease. Alzheimer’s disease is a most significant unmet medical need in modern societies. The market opportunity for effective drugs is projected to exceed $5 billion annually. Soluble Abeta oligomers are now widely recognized as a key culprit in the disease process. They inhibit synaptic function, triggering early memory deficits and initiating nerve cell degeneration, and they are able to directly initiate downstream pathological events in Alzheimer’s disease. Soluble Abeta oligomers were discovered by Acumen’s founders, and the company holds dominant IP in this area. Acumen is involved in drug discovery and development programs for therapeutics targeting amyloid-beta oligomers, actively focusing on immunotherapy (ADDL-Select™ antibodies). The lead anti-ADDL antibody, ACU-193, is in advanced preclinical development. A small molecule ADDL assembly blocker program is actively pursued by Merz Pharmaceuticals, GmbH in a partnered program. ACU-193 is a fully humanized, IgG2 monoclonal antibody that binds synaptotoxic soluble Abeta oligomers with high affinity and selectivity, and is distinct from other antibodies binding to Abeta (e.g., bapineuzumab, solanezumab, crenezumab, gantenerumab), which are designed to lower the Abeta load in the brain. Nanomolar affinity for soluble Abeta oligomer binding has been measured by various methods, with insignificant binding to Abeta monomers, amyloid plaques or vascular amyloid in the brain. ACU-193 shows no cross-reactive binding to other proteins. ACU-193 is expected to improve synaptic function and memory processes of Alzheimer patients. Efficacy of ACU-193 in vitro has been demonstrated in neuronal cell cultures. Abeta soluble oligomer engagement and efficacy of ACU-193 in vivo has been demonstrated in a transgenic mouse model of Alzheimer’s disease. ACU-193 exhibits linear, dose-dependent pharmacokinetics, biodistribution, and brain penetration typical for therapeutic antibodies. Exploratory safety and toxicity studies in monkeys revealed an overall excellent safety profile for ACU-193. Clinical development plans for ACU-193 reflect the availability of biomarker assays and the expectation that behavioral efficacy is achieved relatively quickly. It is anticipated that initial evidence for efficacy will be obtained in a Phase Ib study of relatively short duration and cost.
TECHNOLOGY :
The recently announced clinical results for bapineuzumab and solanuzumab strongly support the rationale for developing a selective soluble A? oligomer immunotherapy such as ACU-193. If one considers the distribution and levels of the various A? species in vivo, the challenges of modulating the levels of soluble A? oligomers, which are by far the most toxic of all A? species, becomes apparent. Although soluble A? oligomers are the most toxic species, they are present in the CSF at very low pg/mL levels. In contrast A?40 monomer, A?42 monomer and amyloid plaques are present at levels that are orders of magnitude higher. Because of the dynamic equilibrium between A? species, significant changes in A? monomer and amyloid plaque levels are required to significantly affect the levels of soluble A? oligomers. This understanding is the basis for Acumen’s focus on soluble A? oligomer antibodies; we target the most toxicologically relevant A? species. This selectivity is what differentiates ACU-193 from essentially all other immunotherapies in development, such as bapineuzumab and crenezumab that broadly bind all A? species, solanuzumab or ponezumab which bind monomers, or mAb158, gantenerumab, or BIIB037 that bind fibrillic A?. These are some of the key aspects of ACU-193, which is: • Expected to deliver acute behavioral benefits in relatively short timeframes (clinical POC in 3 month Aricept/Memantine like trails); • Expected to be an effective stand-alone or co-therapy with other A? or tau directed therapies. • >500x selective for soluble A? oligomers relative to monomeric or fibrillic A? and distinctly different from other A? directed immunotherapies (e.g., bapineuzumab and crenezumab that broadly bind all A? species, solanuzumab or ponezumab that bind monomers, or mAb158, gantenerumab, or BIIB037 that bind fibrillic A?). • Directed to the most toxic A? species with significantly increased potential for therapeutic efficacy based on in vivo levels of A? species (monomeric and fibrillic A? levels in brain of human AD patients are orders of magnitude higher than soluble A? oligomer levels). • The result of an 8-year, multi-million dollar program by Merck & Co. • In a clinically viable, modified IgG2 framework, with good PK/PD, brain penetration, target engagement, efficacy, and safety properties. • Produced in stable production cell lines, in an established manufacturing process and formulation suitable for storage and administration. • Basis of an A? soluble oligomer biomarker and PK assay in a commercial format. • Claimed in composition of matter and methods of used patents first filed in 2010. Acumen is seeking a collaborative, risk sharing partnership with pharmaceutical companies that has the expertise, resources, and commitment to rapidly advance ACU-193 to phase Ib/IIa POC clinical trials. We welcome your feedback on the program and the opportunity to provide additional details should you be interested in the unique risk/reward profile of partnering with Acumen to advance ACU-193 to clinical trials.
OBJECTIVES :
Networking
COMPANY INFORMATION :

Close
Default_logo

Agile DiscoveryPartners

visit website request a meeting with this company
Agile DiscoveryPartners,a CRO, co-funded by a French scientist, has proven expertise in the discovery of small molecules in inflammation and CNS
More ?
COMPANY :
We are a company focused on small molecule drug discovery dedicated to bringing forward quality products.Although we are currently a CRO, our vision is to expand and start our own research programs.
OBJECTIVES :
We are looking for collaborative partnerships
COMPANY INFORMATION :

Close
Default_logo

Crystal Bioscience

visit website request a meeting with this company
We make affinity matured, highly specific monoclonal antibodies to targets that elude other platforms.
More ?
COMPANY :
We harness our proprietary technologies for making fully human monoclonal antibodies and the unique attributes of the chicken immune system to develop novel therapeutic candidate monoclonals. Our typical clients have high value targets such as GPCRs that have eluded conventional technologies such as mouse hybridomas and phage display.
TECHNOLOGY :
Our proprietary platforms include the GEM technology which allows us to identify plasma cells from immunized animals or human PBLs producing antigen specific antibody. We then recover the affinity matured IgH and IgL pairs that form the functional immunoglobulin therapeutic candidate. Our internal pipeline includes GPCR candidates. The range of targets provided by clients includes GPCRs, receptor proteins, cancer -related intracellular proteins and secreted cytokines.
OBJECTIVES :
We are looking for partners with whom we can develop therapeutic candidates. We are also seeking clients with targets that have proved to be intractable using more conventional antibody discovery platforms.
COMPANY INFORMATION :

Close
Thumb_1347574288_gne-logo-member-of-roche-group-jpg

Genentech, Inc.

visit website request a meeting with this company
We use cutting-edge science to create and deliver innovative medicines around the globe.
More ?
COMPANY :
Considered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for more than 35 years, using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Today, Genentech is among the world's leading biotech companies, with multiple products on the market and a promising development pipeline. In March 2009, Genentech became a member of the Roche Group. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech's South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech Research and Early Development operates as an independent center within Roche.
OBJECTIVES :
Genentech brings its innovative and entrepreneurial spirit to collaborations. Today, over half of Genentech’s pipeline and marketed products involve some form of external collaboration. Genentech’s business development team employs a flexible style, tailoring collaboration structures to meet each partner’s needs. Partnership structures often include collaborative research with funding by Genentech and downstream financial consideration ranging from traditional milestone and royalty deals to acquisition options. Genentech consistently strives to create collaboration structures that maximize value for each partner. A successful collaboration relies upon the partners’ complementary scientific contributions as well as a productive business relationship. Genentech typically devotes an alliance manager as the primary point of contact for business and relationship matters after the collaboration begins. With responsive alliance management in place, both teams can stay focused on advancing science and delivering benefit to patients.
COMPANY INFORMATION :

Close
Thumb_1347895872_hcramerica-logo-jpg

Harrison Clinical Research America

visit website request a meeting with this company
For 25 years and counting, Harrison Clinical Research is a global company focused on enabling and supporting the innovation and development of better therapies in healthcare.
More ?
COMPANY :
Harrison Clinical Research, a globally working CRO (ISO 9001) with offices in Europe, Israel and USA, offers full service (including development strategy, project management and performance, monitoring, data management, biostatistics, medical writing, auditing, training, outsourcing) for clinical phase l (in own clinical unit) to phase IV trials.
OBJECTIVES :
We are looking to meet sponsors across therapeutic areas who will benefit from an experienced CRO that knows the complexities of today's trials and knowledge of the unique needs of emerging biotech companies.
COMPANY INFORMATION :

Close
Thumb_1348615508_portola_logo-gif

Portola Pharmaceuticals

visit website request a meeting with this company
Portola is engaged in the discovery and development of therapies for thrombosis, auto-immune and hematologic cancers
More ?
COMPANY :
Portola Pharmaceuticals is a biopharmaceutical company that discovers and develops innovative therapeutics based on targets with established proof of concept that are designed to provide significant advances over current treatments for cardiovascular and autoimmune/inflammatory diseases. Portola scientists have successfully collaborated for over 15 years on the discovery and development of novel small molecule agents targeting platelets, coagulation pathways and protein kinases. Portola has independently initiated a Phase 3 study of its lead molecule, betrixaban, a novel, once-daily Factor Xa inhibitor for venous thromboembolism (VTE) prevention in acute medically ill patients
OBJECTIVES :
Ex-US development and commercialization of Portola molecules or US in-licensing opportunities for hospital or specialty based therapeutics.
COMPANY INFORMATION :

Close
Thumb_1347564756_teikoku_logo-gif

Teikoku Pharma USA

visit website request a meeting with this company
International Specialty Pharmaceutical Company
More ?
COMPANY :
Japanese Pharmaceutical Company, with therapeutic focus in the areas of CNS, PAIN and Oncology. Main product is Lidoderm for PHN.
TECHNOLOGY :
Transdermal, Injectable.
OBJECTIVES :
Seeking to in-license and acquire products.
COMPANY INFORMATION :

Close
Thumb_1348767428_logo-small-jpg

Trellis Bioscience

visit website request a meeting with this company
Trellis leverages its proprietary microscopic, multiplexed assay technology (CellSpot) to discover best in class mAbs directly from human blood cells.
More ?
COMPANY :
Trellis is venture backed, with a strong interest in partnering to leverage our unique mAb discovery technology. Current clinical candidates available for licensing are directed to RSV, to CMV, and to Influenza. Pipeline projects include bacterial targets as well as cancer targets.
OBJECTIVES :
Trellis seeks partners with complementary expertise in target discovery and in clinical development of the mAbs we discover.
COMPANY INFORMATION :

Close
Default_logo

UCSF

visit website request a meeting with this company
The University of California, San Francisco (UCSF) is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.
More ?
COMPANY :
A hallmark of UCSF excellence is a spirit of collaboration among all disciplines that carries through its wide spectrum of patient care, research and education programs, fostering an environment of innovation and discovery. The result is groundbreaking life sciences research and world-class health care that support UCSF’s mission: advancing health worldwide™. Research programs in the basic, clinical, social and behavioral, and population sciences are recognized internationally. Preeminent faculty, who are conducting basic science investigations at the genetic, cellular, molecular and systems level, are unmasking the fundamental mechanisms of biology. And acclaimed faculty conducting investigations involving humans are discovering new solutions for preventing and treating a wide array of diseases, including cardiovascular disease, neurological disorders, cancer, diabetes, genetic disorders, immunological and infectious disease, and reproductive and developmental disorders. UCSF produced more than 600 patents between 2000 and 2009, a greater number than any other UC campus. From 2008 to 2009, UCSF patents brought in an average annual income of $64 million. In addition, UCSF has provided the innovative spark for an estimated 90 life sciences start-up companies that were spawned or spun off from its labs. The research enterprise also is stimulated through partnerships with business, industry and research organizations. In an effort to further support this effort, UCSF over the past two years revamped and streamlined its approach to industry partnerships to help move research more quickly and strategically from the laboratory to clinical trials and patient treatment.
TECHNOLOGY :
UCSF has over 1600 active inventions under management in a variety of areas including therapeutics, medical devices, software, research tools, and diagnostics.
OBJECTIVES :
Collaborators to advance early stage life science discoveries made at UCSF to products and services used to benefit patients.
COMPANY INFORMATION :
  • Address :
      UCSF Office of Innovation, Technology & Alliances University of California, San Francisco 3333 California Street| Suite S-11 - San Francisco - CA
  • Website :
     http://www.ucsf.edu

Close